The potential for side effects is heightened, the cost is substantial, and the level of medical oversight required is considerable
This could change, however, under the Treat and Reduce Obesity Act, which would allow Medicare Part D to cover these medications
The most important challenge is understanding what weve actually found
Nowhere near settled, and absolutely not a reason to swap any part of actual cancer treatment
Abstract Glucagon-like peptide 1 receptor agonists (GLP1RAs) are widely used for the treatment of type 2 diabetes mellitus (T2DM) and, at higher doses, obesity
Lifestyle intervention for gastroesophageal reflux disease: a national multicenter survey of lifestyle factor effects on gastroesophageal reflux disease in China